BDX Becton Dickinson

Q2 2025 10-Q

Filed: Aug 7, 2025Period ending Jun 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Becton Dickinson (BDX) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 7, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• New transaction risk: combination with Waters may not close by Q1 2026, pending regulatory and IRS approvals
• Updated operational risk: separation and combination may disrupt business and divert management attention

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$5.5B

▲ +10.4% YoY▲ +4.5% QoQ

Net Income

$574M

▲ +17.9% YoY▲ +86.4% QoQ

Operating Margin

16.0%

▲ +395bp YoY▲ +563bp QoQ

Net Margin

10.4%

▲ +66bp YoY▲ +458bp QoQ

EPS (Diluted)

$1.99

▲ +18.5% YoY▲ +86.0% QoQ

Operating Cash Flow

$1.2B

▼ -6.0% YoY▲ +643.3% QoQ

Source: XBRL data from Becton Dickinson Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Becton Dickinson Quarterly Reports

Q4 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Becton Dickinson

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.